Evidence map›Paper›PMID 39497266›Full record

ArticlemAbs

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies.

Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007.Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yizhou ZhangShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Ruicheng WeiShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Ge SongShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Xinyi YangShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Mengli ZhangShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Wei LiuShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Aiying XiongShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Xuehan ZhangShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Qianhao LiShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Wan-Jen YangShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Chencheng HanShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Rui LiuShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.
Chen HuClinical Development, Shanghai Henlius Biotech, Inc., Shanghai, China.
Qingyu WangClinical Development, Shanghai Henlius Biotech, Inc., Shanghai, China.
Jun ZhuExecutive Director Office, Shanghai Henlius Biotech, Inc., Shanghai, China.
Yongqiang ShanShanghai Innovation Center, Shanghai Henlius Biotech, Inc., Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With more than 20 anti-PD-1/PD-L1 antibodies currently marketed, anti-PD-1 therapy has become a cornerstone of tumor immunotherapy. These agents, however, exhibit notable disparities in their characteristics and clinical performance. For instance, in the field of small cell lung cancer (SCLC) where the majority of anti-PD-1 antibodies have yielded limited success, serplulimab produced impressive survival improvements and was approved for this indication by China's National Medical Products Administration. Serplulimab's marketing authorization application also received a positive opinion from the European Medicines Agency. Nevertheless, the molecular mechanism underpinning serplulimab's superiority over its competitors remains elusive. We characterized the differences between serplulimab with approved PD-1/PD-L1 inhibitors (pembrolizumab and nivolumab) in terms of their binding features and functions

Indexed as

Antibodies, Monoclonal, HumanizedLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 ReceptorAnimalsAntigens, CDCell Line, TumorHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsMiceNivolumabReceptors, ImmunologicAntibodies, Monoclonal, HumanizedAntigens, CDImmune Checkpoint InhibitorsLag3 protein, humanLymphocyte Activation Gene 3 ProteinNivolumabPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTIGIT protein, humanAnti-PD-1/PD-L1serplulimabtumor immunotherapy

Identifiers

PMID39497266
PMCPMC11540081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.